Loading
Hologic Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 May 2025.
Hologic Inc: what insiders have been doing
This page follows insider dealings at Hologic Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Marlborough, United States. The group dates from 1985. Between 18 October 2025 and 18 October 2026, 18 insiders published 57 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Over the last twelve months, not one insider purchase of Hologic Inc stock was filed. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (5,810 companies, median 19 filings), a count of 57 filings is above the norm. Since 2016, the database holds 1 purchase and 15 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 27 September 2025 lists revenue at 4.10 bn USD and net income at 565.7 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
248
Thresholds
n/a
Buy Volume
€266,013
1 ops. · all time
Sell Volume
€7M
15 ops. · all time
Who traded when
BuySaleMartin D. Madaus1 buy
Since the insiders bought
- +8.0%Entry US$62.17 · Close at T+90 US$67.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Hologic Inc Hold (neutral), based on 9 analysts. Average price target: US$76.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,419 of 24,148 companies
57.1
score / 100
Value49
Quality65
FCF yld5.3%
Earn yld3.3%
EV/EBITDA17.8x
ROE11%
Gross mgn52%
Net mgn14%
Debt/EBITDA2.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
US$76.01
Analyst consensus
9 analystsHold
US$76.00Target US$76.67(+1%)US$78.00
Income statement
RevenueUS$4.1B
Gross profitUS$2.1B52% margin
EBITDAUS$1.1B27% margin
Net incomeUS$565.7M13.2% margin
Valuation
PER (trailing)31.5x
PER (forward)15.7x
P/Book3.2x
Beta0.70
Balance sheet & cash
Market capUS$17B
Total debtUS$2.6B
Free Cash FlowUS$904.7M
Debt / Equity48%
Profitability & ownership
ROE10.9%
ROA7.4%
% insiders0.8%
% institutions96.5%
Last declaration on 9 April 2026
Declarations248 total
25,784 sharesCommon StockSEC:0000859737-26-000077:0
23,026 sharesCommon StockSEC:0000859737-26-000081:0
28,052 sharesCommon StockSEC:0000859737-26-000083:0
4,932 sharesCommon StockSEC:0000859737-26-000069:0
7,371 sharesCommon StockSEC:0000859737-26-000071:0
50,526 sharesCommon StockSEC:0000859737-26-000073:0
8,358 sharesCommon StockSEC:0000859737-26-000075:0
17,964 sharesCommon StockSEC:0000859737-26-000059:0
15,370 sharesCommon StockSEC:0000859737-26-000061:1
7,603 sharesCommon StockSEC:0000859737-26-000079:0
6,626 sharesCommon StockSEC:0000859737-26-000061:0
16,146 sharesCommon StockSEC:0000859737-26-000063:0
5,445 sharesCommon StockSEC:0000859737-26-000067:1
1,423,837 sharesCommon StockSEC:0000859737-26-000065:0
1,146,829 sharesCommon StockSEC:0000859737-26-000065:1
5,396 sharesCommon StockSEC:0000859737-26-000067:0
77,694 sharesCommon StockSEC:0000859737-26-000085:0
150,735 sharesCommon StockSEC:0000859737-26-000087:0
41,462 sharesCommon StockSEC:0000859737-26-000089:0
17,644 sharesCommon StockSEC:0000859737-26-000091:0
134,039 sharesCommon StockSEC:0000859737-26-000093:0
185 shares@ US$75.3622.8% of flowCommon StockSEC:0000859737-26-000033:0
3,190 sharesCommon StockSEC:0000859737-26-000031:0
3,190 sharesCommon StockSEC:0000859737-26-000029:0
3,190 sharesCommon StockSEC:0000859737-26-000027:0
25 of 248 declarations
About Hologic Inc
Hologic Inc. (ticker: HOLX) is a U.S.-based medical technology company focused on women’s health and formerly listed on the NASDAQ market in the United States. Headquartered in Marlborough, Massachusetts, Hologic was founded in 1985 and has built its franchise around clinically proven technologies that support screening, diagnosis, and treatment across women’s health pathways. Its business model combines recurring consumables, installed equipment, and innovation-led product upgrades, making it a differentiated medtech platform rather than a pure-play diagnostics company. ([hologic.com](https://www.hologic.com/about?utm_source=openai))
Hologic reports its operations through four principal segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment includes molecular testing and cytology solutions used in disease screening and detection, with particular strength in cervical health and sexual health testing. Breast Health is one of the company’s core pillars, spanning mammography systems, breast biopsy tools, localization technologies, and related imaging solutions used from screening through treatment. GYN Surgical includes products designed to address gynecologic conditions such as abnormal uterine bleeding, while Skeletal Health covers bone-densitometry and related imaging solutions. This multi-segment structure gives Hologic a broad clinical footprint and helps balance growth across hospital, outpatient, and women’s health settings. ([fintel.io](https://fintel.io/doc/sec-hologic-inc-859737-10k-2025-november-18-20410-6130?utm_source=openai))
Read moreShow less
From a competitive standpoint, Hologic holds a meaningful position in women’s health diagnostics and breast imaging, supported by recognized brands, a substantial installed base, and a global commercial network. The company says it operates in 36 countries and holds more than 4,100 patents, which underscores the depth of its intellectual property and the barriers to entry in several of its end markets. Its competitive strategy centers on precision, workflow efficiency, and clinical confidence, with increasing emphasis on AI-enabled mammography and next-generation biopsy solutions. ([hologic.com](https://www.hologic.com/about?utm_source=openai))
Recent developments have been especially important. In October 2025, Hologic announced a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, and the deal was subsequently approved and completed in 2026, taking the company private. The company also received CE marking in February 2025 for its Affirm Contrast Biopsy software, and it continued expanding digital pathology capabilities later in 2025. Taken together, these events highlight a company that remains strategically focused on women’s health innovation while entering a new ownership structure. ([investor.hologic.com](https://investor.hologic.com/press-releases/press-release-details/2025/Hologic-to-be-Acquired-by-Blackstone-and-TPG-for-up-to-79-per-Share/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
